Gilead Sciences (GILD) is Downgraded by Maxim Group to Hold

Gilead Sciences (GILD) was Downgraded by Maxim Group to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Maxim Group advised their investors in a research report released on Apr 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .Citigroup Initiated Gilead Sciences on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $110.Shares were Reiterated by Maxim Group on Feb 12, 2016 to “Buy” and Lowered the Price Target to $ 115 from a previous price target of $137 .

On the company’s financial health, Gilead Sciences reported $3.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.34 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $2.98. The company had revenue of $8506.00 million for the quarter, compared to analysts expectations of $8163.83 million. The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.

Gilead Sciences closed down -0.61 points or -0.60% at $100.72 with 85,85,754 shares getting traded on Wednesday. Post opening the session at $101.3, the shares hit an intraday low of $100.15 and an intraday high of $101.78 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Apr 21, 2016, Gregg H Alton (EVP, Corp & Med Affairs) sold 40,000 shares at $100.01 per share price. According to the SEC, on Apr 5, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $92.59 per share price. On Apr 5, 2016, John F Milligan (President and CEO) sold 112,000 shares at $94.71 per share price, according to the Form-4 filing with the securities and exchange commission.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Gilead Sciences

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.